$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $84K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 2,400 shares of Pharvaris N.V. (PHVS) at $35.10 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Jun 29, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

A director’s pre-arranged open-market sale is typically low-signal for fundamentals; traders may only adjust short-term sentiment or monitor for future non-10b5-1 activity.

02

Market read

Disclosed insider selling amount ($84.25K) is modest and explicitly pre-arranged, implying limited trading edge.

03

What to watch

Insider sales under 10b5-1 can be scheduled regardless of company outlook; the filing doesn’t include any new operational or clinical catalyst.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-29 (after-hours) for a same-day 10b5-1 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

SEC Form 4 shows director Schikan sold 2,400 PHVS shares on 2026-06-29 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity/tax-driven under the 10b5-1 plan, so it shouldn’t be treated as a bearish fundamental signal.

Key entities

  • Pharvaris N.V.

    Company subject of the Form 4 insider transaction disclosure.

  • Schikan Johannes Gerardus Christiaan Petrus

    Director who sold 2,400 shares on 2026-06-29 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.